JP2019535797A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019535797A5 JP2019535797A5 JP2019528685A JP2019528685A JP2019535797A5 JP 2019535797 A5 JP2019535797 A5 JP 2019535797A5 JP 2019528685 A JP2019528685 A JP 2019528685A JP 2019528685 A JP2019528685 A JP 2019528685A JP 2019535797 A5 JP2019535797 A5 JP 2019535797A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- prlr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108010002519 Prolactin Receptors Proteins 0.000 claims description 67
- 102100029000 Prolactin receptor Human genes 0.000 claims description 67
- 239000000427 antigen Substances 0.000 claims description 62
- 102000036639 antigens Human genes 0.000 claims description 62
- 108091007433 antigens Proteins 0.000 claims description 62
- 239000012634 fragment Substances 0.000 claims description 62
- 239000000611 antibody drug conjugate Substances 0.000 claims description 48
- 229940049595 antibody-drug conjugate Drugs 0.000 claims description 48
- 210000004027 cell Anatomy 0.000 claims description 36
- 150000001413 amino acids Chemical class 0.000 claims description 31
- 108010057464 Prolactin Proteins 0.000 claims description 26
- 102000003946 Prolactin Human genes 0.000 claims description 26
- 230000001404 mediated effect Effects 0.000 claims description 26
- 229940097325 prolactin Drugs 0.000 claims description 26
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 25
- 230000011664 signaling Effects 0.000 claims description 24
- VWUXBMIQPBEWFH-WCCTWKNTSA-N Fulvestrant Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 claims description 21
- 229960002258 fulvestrant Drugs 0.000 claims description 18
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 8
- 208000026310 Breast neoplasm Diseases 0.000 claims description 8
- 101001123448 Homo sapiens Prolactin receptor Proteins 0.000 claims description 7
- NZNMSOFKMUBTKW-UHFFFAOYSA-N cyclohexanecarboxylic acid Chemical compound OC(=O)C1CCCCC1 NZNMSOFKMUBTKW-UHFFFAOYSA-N 0.000 claims description 6
- 210000004881 tumor cell Anatomy 0.000 claims description 6
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 229910052805 deuterium Inorganic materials 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- JSHOVKSMJRQOGY-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 4-(pyridin-2-yldisulfanyl)butanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCSSC1=CC=CC=N1 JSHOVKSMJRQOGY-UHFFFAOYSA-N 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 102000001712 STAT5 Transcription Factor Human genes 0.000 claims description 2
- 108010029477 STAT5 Transcription Factor Proteins 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000010261 cell growth Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 102000015694 estrogen receptors Human genes 0.000 claims description 2
- 108010038795 estrogen receptors Proteins 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- -1 mc-val-cit Chemical compound 0.000 claims description 2
- 230000011278 mitosis Effects 0.000 claims description 2
- AMKBTTRWLGVRER-OFVILXPXSA-N n-[(2s)-1-[[(2s)-5-(carbamoylamino)-1-[4-(hydroxymethyl)anilino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]-6-(2,5-dioxopyrrol-1-yl)hexanamide Chemical compound N([C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=O)C(=O)NC=1C=CC(CO)=CC=1)C(=O)CCCCCN1C(=O)C=CC1=O AMKBTTRWLGVRER-OFVILXPXSA-N 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 35
- 239000000562 conjugate Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 description 60
- 238000011260 co-administration Methods 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662427534P | 2016-11-29 | 2016-11-29 | |
| US62/427,534 | 2016-11-29 | ||
| PCT/US2017/063476 WO2018102304A1 (en) | 2016-11-29 | 2017-11-28 | Methods of treating prlr positive breast cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019535797A JP2019535797A (ja) | 2019-12-12 |
| JP2019535797A5 true JP2019535797A5 (OSRAM) | 2021-02-25 |
| JP7174699B2 JP7174699B2 (ja) | 2022-11-17 |
Family
ID=60703124
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019528685A Active JP7174699B2 (ja) | 2016-11-29 | 2017-11-28 | Ｐｒｌｒ陽性乳癌の治療方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10925971B2 (OSRAM) |
| EP (1) | EP3548514A1 (OSRAM) |
| JP (1) | JP7174699B2 (OSRAM) |
| KR (1) | KR20190091290A (OSRAM) |
| CN (1) | CN110382534B (OSRAM) |
| AU (1) | AU2017366873A1 (OSRAM) |
| CA (1) | CA3044534A1 (OSRAM) |
| EA (1) | EA201900312A1 (OSRAM) |
| IL (1) | IL266917B2 (OSRAM) |
| MX (1) | MX2019006131A (OSRAM) |
| WO (1) | WO2018102304A1 (OSRAM) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201405468QA (en) | 2012-03-14 | 2014-10-30 | Regeneron Pharma | Multispecific antigen-binding molecules and uses thereof |
| US11352446B2 (en) | 2016-04-28 | 2022-06-07 | Regeneron Pharmaceuticals, Inc. | Methods of making multispecific antigen-binding molecules |
| BR112019016336A2 (pt) * | 2017-02-10 | 2020-03-31 | Regeneron Pharmaceuticals, Inc. | Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto. |
| TW201836647A (zh) | 2017-04-06 | 2018-10-16 | 美商艾伯維有限公司 | 抗－ｐｒｌｒ抗體藥物軛合物（ａｄｃ）及其用途 |
| KR20200118151A (ko) | 2018-02-07 | 2020-10-14 | 리제너론 파마슈티칼스 인코포레이티드 | 치료 단백질 전달을 위한 방법 및 조성물 |
| KR20240105964A (ko) * | 2022-12-29 | 2024-07-08 | 주식회사 삼양홀딩스 | 약동학적 특성이 우수한 풀베스트란트의 약학 조성물 및 그 제조 방법 |
| CN118834297A (zh) * | 2023-04-24 | 2024-10-25 | 深圳真实生物医药科技有限公司 | 泌乳素受体抗体及其用途 |
| WO2025192691A1 (ja) * | 2024-03-14 | 2025-09-18 | 東レ株式会社 | 癌の治療及び／又は予防用医薬組成物 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
| US6429186B1 (en) | 1991-05-10 | 2002-08-06 | Genentech, Inc. | Ligand antagonists for treatment of breast cancer |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ATE366114T1 (de) | 1998-05-12 | 2007-07-15 | Greenville Hospital System | Verwendung von anti-prolaktin agentien zur behandlung von krebs |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6867187B2 (en) | 2000-12-22 | 2005-03-15 | Trustees Of The University Of Pennsylvania | Composition and method for modulating somatolactogenic function |
| US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
| US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
| WO2005058232A2 (en) | 2003-12-11 | 2005-06-30 | Tercica, Inc. | Methods and compositions for the treatment of prolactin-receptor related disorders |
| US8754031B2 (en) | 2004-03-08 | 2014-06-17 | Oncolix, Inc. | Use of prolactin receptor antagonists in combination with an agent that inactivates the HER2/neu signaling pathway |
| US7422899B2 (en) | 2005-10-05 | 2008-09-09 | Biogen Idec Ma Inc. | Antibodies to the human prolactin receptor |
| WO2007051112A2 (en) | 2005-10-24 | 2007-05-03 | Invitrogen Corporation | Serum prolactin binding protein in epithelial carcinoma |
| CA2652976C (en) | 2006-06-02 | 2015-08-11 | Regeneron Pharmaceuticals, Inc. | High affinity antibodies to human il-6 receptor |
| WO2008002295A1 (en) | 2006-06-27 | 2008-01-03 | Thomson Licensing | Performance aware peer-to-peer video-on-demand |
| EP3018144A1 (en) | 2006-08-18 | 2016-05-11 | XOMA Technology Ltd. | Prlr-specific antibody and uses thereof |
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| NO347649B1 (no) | 2006-12-14 | 2024-02-12 | Regeneron Pharma | Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse. |
| WO2009010398A1 (en) | 2007-07-18 | 2009-01-22 | Novo Nordisk A/S | Stabilized prolactin receptor antagonists |
| BRPI0911442A2 (pt) | 2008-04-30 | 2019-03-12 | Immunogen, Inc. | conjugados potentes e ligantes hidrofílicos |
| JO3182B1 (ar) | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| EP2332995A1 (en) | 2009-12-10 | 2011-06-15 | Bayer Schering Pharma Aktiengesellschaft | Neutralizing prolactin receptor antibodies and their therapeutic use |
| WO2012136519A1 (en) | 2011-04-06 | 2012-10-11 | Bayer Pharma Aktiengesellschaft | Use of neutralizing prolactin receptor antibodies for the treatment and prevention of antiestrogen-resistant breast cancer |
| EP2530089A1 (en) | 2011-06-03 | 2012-12-05 | Bayer Pharma Aktiengesellschaft | Neutralising prolactin receptor antibody Mat3 and its therapeutical use |
| CN102746402A (zh) | 2012-07-09 | 2012-10-24 | 南京医科大学 | 全人源抗人催乳素受体单链抗体及其应用 |
| US8883979B2 (en) | 2012-08-31 | 2014-11-11 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| MX382301B (es) | 2012-12-24 | 2025-03-13 | Abbvie Inc | Proteinas de union al receptor de prolactina y usos de las mismas. |
| KR102306490B1 (ko) | 2013-03-15 | 2021-09-28 | 리제너론 파아마슈티컬스, 인크. | 생물학적 활성 분자, 그의 접합체 및 치료 용도 |
| CA2906101A1 (en) | 2013-03-15 | 2014-09-18 | Bayer Healthcare Llc | Anti-prolactin receptor antibody formulations |
| TWI641620B (zh) * | 2013-08-21 | 2018-11-21 | 再生元醫藥公司 | 抗－ｐｒｌｒ抗體及其用途 |
| US9545451B2 (en) * | 2013-08-21 | 2017-01-17 | Regeneron Pharmaceuticals, Inc. | Anti-PRLR antibodies and methods for killing PRLR-expressing cells |
| SG11201601230RA (en) | 2013-08-26 | 2016-03-30 | Regeneron Pharma | Pharmaceutical compositions comprising macrolide diastereomers, methods of their synthesis and therapeutic uses |
| CN107995912A (zh) | 2015-03-27 | 2018-05-04 | 里珍纳龙药品有限公司 | 美登素类衍生物、其偶联物和使用方法 |
-
2017
- 2017-11-28 WO PCT/US2017/063476 patent/WO2018102304A1/en not_active Ceased
- 2017-11-28 CA CA3044534A patent/CA3044534A1/en active Pending
- 2017-11-28 KR KR1020197018219A patent/KR20190091290A/ko not_active Ceased
- 2017-11-28 JP JP2019528685A patent/JP7174699B2/ja active Active
- 2017-11-28 US US15/824,546 patent/US10925971B2/en not_active Expired - Fee Related
- 2017-11-28 IL IL266917A patent/IL266917B2/en unknown
- 2017-11-28 MX MX2019006131A patent/MX2019006131A/es unknown
- 2017-11-28 EA EA201900312A patent/EA201900312A1/ru unknown
- 2017-11-28 CN CN201780084656.8A patent/CN110382534B/zh not_active Expired - Fee Related
- 2017-11-28 AU AU2017366873A patent/AU2017366873A1/en not_active Abandoned
- 2017-11-28 EP EP17817499.1A patent/EP3548514A1/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2019535797A5 (OSRAM) | ||
| JP6923602B2 (ja) | 抗アクチビンａ抗体及びその使用 | |
| AU2018250301B2 (en) | Anti-ICOS agonist antibodies and uses thereof | |
| JP2022191301A5 (OSRAM) | ||
| JP2018534933A5 (OSRAM) | ||
| KR102121678B1 (ko) | β-KLOTHO, FGF 수용체 및 이들의 복합체에 결합하는 인간 항원 결합 단백질 | |
| TW201024310A (en) | Antitumor combinations containing antibodies recognizing specifically CD38 and vincristine | |
| JP2020528768A5 (OSRAM) | ||
| JP2017522861A5 (OSRAM) | ||
| JP2018500014A5 (OSRAM) | ||
| JP2015503909A5 (OSRAM) | ||
| RU2013155906A (ru) | Антитела анти-angptl3 и их применение | |
| RU2019111722A (ru) | Антитела против siglec-15 и способы их применения | |
| RU2012156938A (ru) | Антитела против gdf8 человека | |
| JP2004510752A5 (OSRAM) | ||
| JP2016531915A5 (OSRAM) | ||
| JP2017536414A5 (OSRAM) | ||
| JP2020510039A5 (OSRAM) | ||
| CN107771081A (zh) | 用gdf8抑制剂增加力量和功能的方法 | |
| CA3118777A1 (en) | Methods of treating graves' ophthalmopathy using anti-fcrn antibodies | |
| CN105188763A (zh) | 抗体药物缀合物和相应的抗体 | |
| EP1706143A1 (en) | Cd40 antibody formulation and methods | |
| JP2006512899A5 (OSRAM) | ||
| JP2010520290A5 (OSRAM) | ||
| KR20230119670A (ko) | 인간 카나비노이드 1(cb1) 수용체 결합 항체 |